Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- 14 New Drugs Including Micafungin to Be Included in NHI Price List
December 9, 2002
- Kyorin: New Products Drive Increases in 1st-half Sales, Profits
December 2, 2002
- Azwell: "Painful Reforms" Bring Return to Profitability
December 2, 2002
- MEDICAL FACILITIES & NURSING CARE NEWS IN BRIEF
December 2, 2002
- Mochida: NHI Price Cuts Affect Semiannual Sales, Profits
December 2, 2002
- Toho: Cost-cutting, Higher Margins Boost Sales, Profits
December 2, 2002
- Meiji Seika Discovers Enzymes Inactivating Abnormal Prion Protein
December 2, 2002
- Rohto: Profits Jump Despite Modest Increase in Sales
December 2, 2002
- Tanabe Seiyaku to Co-develop Altana's Roflumilast
December 2, 2002
- DIAGNOSTIC NEWS IN BRIEF
December 2, 2002
- Kissei: NHI Price Cut, Sluggish Sales Hit Sales, Profits
December 2, 2002
- Nippon Shinyaku's Cylocide Gets New Indication for Malignant Lymphoma
December 2, 2002
- World Self-Medication Industry 14th General Assembly & 5th Asia Pacific Regional Conference
December 2, 2002
- Zeria: Ethical Drug Sales Down 8.9% in First Half
December 2, 2002
- WEBSITE NEWS
December 2, 2002
- WG to Recommend OTC Drugs to Prevent Lifestyle-related Diseases
December 2, 2002
- Fuso: Sales, Profits Down Due to Lower Sales of Dialysis Products
December 2, 2002
- Otsuka's Schizophrenia Treatment Abilify Obtains Approvable Letter from FDA
December 2, 2002
- Sundrug: Strong Sales Support Expansion Beyond Tokyo Metropolitan Area
December 2, 2002
- Wakamoto: Profits Plummet Due to Increased Costs, R&D Investment
December 2, 2002
ページ
The launch of Elevidys has opened the door to gene therapy for DMD, but research into new treatments is already…
I recently sat down with one of the leading medical directors in Japan to discuss the critical evolution of the medical science liaison (MSL) role.The MSL has transformed from a scientific resource into a strategic partner essential for successful product…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…